The impact of argan oil on plasma lipids in humans: Systematic review and meta‐analysis of randomized controlled trials |
| |
| Authors: | Sorin Ursoniu Amirhossein Sahebkar Maria‐Corina Serban Maciej Banach Lipid and Blood Pressure Meta‐analysis Collaboration Group |
| |
| Affiliation: | 1. Department of Functional Sciences, Discipline of Public Health, Victor Babes University of Medicine and Pharmacy, Timisoara, Romania;2. Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran;3. Neurogenic Inflammation Research Center, Mashhad University of Medical Sciences, Mashhad, Iran;4. School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran;5. Department of Functional Sciences, Discipline of Pathophysiology, Victor Babes University of Medicine and Pharmacy, Timisoara, Romania;6. Department of Hypertension, Chair of Nephrology and Hypertension, Medical University of Lodz, Poland;7. Polish Mother's Memorial Hospital Research Institute (PMMHRI), Lodz, Poland;8. Cardiovascular Research Centre, University of Zielona Gora, Zielona Gora, Poland;9. Lipid and Blood Pressure Meta‐Analysis Collaboration (LBPMC) Group, Poland;10. Polish Lipid Association (PoLA), Poland |
| |
| Abstract: | The study aims to investigate the effect of argan oil on plasma lipid concentrations through a systematic review of the literature and a meta‐analysis of available randomized controlled trials. Randomized controlled trials that investigated the impact of at least 2 weeks of supplementation with argan oil on plasma/serum concentrations of at least 1 of the main lipid parameters were eligible for inclusion. Effect size was expressed as the weighted mean difference (WMD) and 95% confidence interval (95% CI). Meta‐analysis of data from 5 eligible trials with 292 participants showed a significant reduction in plasma concentrations of total cholesterol (WMD: ?16.85 mg/dl, 95% CI ?25.10, ?8.60], p < .001), low‐density lipoprotein cholesterol (WMD: ?11.67 mg/dl, 95% CI ?17.32, ?6.01], p < .001), and triglycerides (WMD: ?13.69 mg/dl, 95% CI ?25.80, ?1.58], p = .027) after supplementation with argan oil compared with control treatment, and plasma concentrations of high‐density lipoprotein cholesterol (WMD: 4.14 mg/dl, 95% CI 0.86, 7.41], p = .013) were found to be increased. Argan oil supplementation reduces total cholesterol, low‐density lipoprotein cholesterol, and triglycerides and increases high‐density lipoprotein cholesterol levels. Additionally, larger clinical trials are needed to assess the impact of argan oil supplementation on other indices of cardiometabolic risk and on the risk of cardiovascular outcomes. |
| |
| Keywords: | Argan oil low‐density lipoprotein cholesterol meta‐analysis total cholesterol triglycerides |
|
|
